Drug Profile
Metatinib
Alternative Names: Metatinib tromethamineLatest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Jiangsu Simcere Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastric cancer; Liver cancer; Solid tumours
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for phase-I development in Gastric-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease) in China (PO, Tablet)